KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Non-Current Debt (2018 - 2021)

Historic Non-Current Debt for Bionano Genomics (BNGO) over the last 4 years, with Q1 2021 value amounting to $14.9 million.

  • Bionano Genomics' Non-Current Debt changed N/A to $14.9 million in Q1 2021 from the same period last year, while for Mar 2021 it was $14.9 million, marking a year-over-year change of. This contributed to the annual value of $16.3 million for FY2020, which is N/A changed from last year.
  • Per Bionano Genomics' latest filing, its Non-Current Debt stood at $14.9 million for Q1 2021.
  • Over the past 5 years, Bionano Genomics' Non-Current Debt peaked at $18.8 million during Q3 2019, and registered a low of $1.8 million during Q2 2020.
  • Over the past 4 years, Bionano Genomics' median Non-Current Debt value was $14.9 million (recorded in 2021), while the average stood at $12.1 million.
  • As far as peak fluctuations go, Bionano Genomics' Non-Current Debt skyrocketed by 10844.42% in 2019, and later tumbled by 9054.71% in 2020.
  • Bionano Genomics' Non-Current Debt (Quarter) stood at $9.0 million in 2018, then skyrocketed by 107.96% to $18.8 million in 2019, then fell by 13.06% to $16.3 million in 2020, then fell by 8.94% to $14.9 million in 2021.
  • Its Non-Current Debt stands at $14.9 million for Q1 2021, versus $16.3 million for Q4 2020 and $1.8 million for Q3 2020.